PCDHA3

Across TCGA pan-cancer cohorts, PCDHA3 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated PCDHA3 data layer compared with 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PCDHA3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHA3 expression acts as an unfavorable survival marker, although some lineages such as UCS and UVM show a favorable association.

LUSC, UCS, and UVM are the cancer types where PCDHA3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.283	0.492	<.001	95	view →
UCS	DFS	Median	II,III,IV	0.589	0.126	<.001	92	view →
UVM	OS	Tertile	II,III,IV	0.950	0.497	<.001	69	view →
KIRP	DFS	Quartile	IV	0.050	1.000	.006	44	view →
LIHC	DFS	Quartile	All	0.325	0.510	.001	38	view →
KIRC	DFS	Median	All	0.908	0.813	.003	31	view →
SKCM	OS	Quartile	III,IV	0.749	0.310	.007	26	view →
STAD	DFS	Tertile	All	0.448	0.601	.012	24	view →
ESCA	OS	Median	IV	0.222	0.698	.006	24	view →
LGG	OS	Median	All	0.942	0.835	.001	18	view →
KICH	DFS	Median	II,III,IV	0.714	0.959	.013	16	view →
PAAD	DFS	Quartile	All	0.532	0.293	.010	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

PCDHA3–LUSC (DFS)

Open the LUSC breakdown →